WallStSmart
FDMT

4D Molecular Therapeutics Inc

NASDAQ: FDMT · HEALTHCARE · BIOTECHNOLOGY

$8.87
+0.68% today

Updated 2026-04-30

Market cap
$479.88M
P/E ratio
P/S ratio
5.63x
EPS (TTM)
$-2.42
Dividend yield
52W range
$3 – $12
Volume
0.8M

4D Molecular Therapeutics Inc (FDMT) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item201720182019202020212022202320242025
Revenue$5.79M$14.13M$6.99M$13.61M$18.04M$3.13M$20.72M$37000.00$85.21M
Revenue growth (YoY)+144.0%-50.6%+94.8%+32.5%-82.7%+562.3%-99.8%+230194.6%
Cost of revenue$13.57M$18.36M$38.72M$53.04M$3.02M$3.88M$97.10M$6.71M$7.63M
Gross profit$-7.78M$-4.23M$-31.73M$-39.43M$18.04M$3.13M$-76.37M$37000.00$77.58M
Gross margin-134.4%-30.0%-454.2%-289.6%100.0%100.0%-368.5%100.0%91.1%
R&D$13.57M$18.36M$43.85M$53.04M$61.36M$80.25M$97.10M$141.30M$195.70M
SG&A$3.49M$6.17M$13.89M$17.24M$28.01M$32.91M$36.49M$46.58M$49.06M
Operating income$-11.27M$-10.40M$-50.76M$-56.66M$-71.33M$-110.03M$-112.87M$-187.84M$-159.55M
Operating margin-194.7%-73.6%-726.7%-416.3%-395.5%-3516.5%-544.6%-507678.4%-187.2%
EBITDA$-10.65M$-9.70M$-44.62M$-55.22M$-68.31M$-106.15M$-108.66M$-181.14M$-151.92M
EBITDA margin-183.9%-68.7%-638.7%-405.7%-378.7%-3392.5%-524.4%-489556.8%-178.3%
EBIT$-11.27M$-10.40M$-45.63M$-56.66M$-71.33M$-110.03M$-112.87M$-187.84M$-159.55M
Interest expense$0.00$0.00$0.00$152000.00$3.04M$6.42M
Income tax
Effective tax rate0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net income$-11.22M$-9.55M$-49.31M$-56.69M$-68.30M$-101.08M$-100.84M$-160.87M$-140.11M
Net income growth (YoY)+14.9%-416.2%-15.0%-20.5%-48.0%+0.2%-59.5%+12.9%
Profit margin-193.8%-67.6%-705.8%-416.5%-378.6%-3230.3%-486.6%-434778.4%-164.4%